The table below shows Beam Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$128.51M
-$103.88M
-$99.75M
-$109.81M
$218.49M
-$38.58M
Capital expenditure
$2.23M
$3.06M
$2.44M
$6.02M
$7.26M
$11.48M
Investing cash flow
$25.27M
-$125.09M
-$53.46M
$25.45M
-$537.34M
-$279.63M
Dividends paid
-
-
-
BEAM operating cash flow (10-K history)
Beam Therapeutics Inc. reported operating cash flow of -$345.10M for fiscal year 2025. That is up 0.6% from -$347.25M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$72.00M (FY 2019) to -$345.10M. Figures come from the company's audited annual reports as filed with the SEC.
